Pulling SEC filings + quote and writing the call…
| Fiscal year | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $15.8M | $20.8M | $9.54M | $12.4M | $206M | $167M | $152M | $82.0M |
| Revenue growth | — | 32.0% | -54.1% | 29.6% | 1566.8% | -19.0% | -8.7% | -46.1% |
| Operating income | -$21.8M | -$25.5M | -$71.5M | -$203M | $12.2M | -$78.2M | -$95.7M | -$76.3M |
| Operating margin | -138.5% | -122.7% | -749.8% | -1641.3% | 5.9% | -46.9% | -62.8% | -93.0% |
| Net income | -$21.8M | -$26.0M | -$72.1M | -$204M | $9.35M | -$29.7M | -$80.9M | -$65.8M |
| Net margin | -138.3% | -125.0% | -756.3% | -1648.0% | 4.5% | -17.8% | -53.1% | -80.2% |
| EPS (diluted) | -$2.16 | -$2.15 | -$3.55 | -$7.74 | $0.35 | -$1.12 | -$3.00 | -$2.40 |
| Fiscal year | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$20.8M | -$6.45M | -$42.9M | -$135M | $32.0M | -$18.1M | -$59.7M | -$74.3M |
| Capital expenditures | $1.48M | $818K | $1.74M | $3.41M | $7.73M | $2.90M | $648K | $230K |
| Free cash flow | -$22.2M | -$7.26M | -$44.6M | -$138M | $24.3M | -$21.0M | -$60.4M | -$74.5M |
| Fiscal year | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|
| Cash & equivalents | $36.7M | $71.4M | $463M | $370M | $392M | $292M | $237M | $231M |
| Total assets | $44.2M | $82.1M | $476M | $393M | $450M | $429M | $344M | $271M |
| Total liabilities | $30.6M | $56.4M | $79.9M | $165M | $180M | $151M | $103M | $57.2M |
| Long-term debt | $9.91M | $15.0M | $13.8M | $40.6M | — | — | — | — |
| Shareholders' equity | $13.6M | $25.8M | $397M | $228M | $270M | $279M | $241M | $214M |
| Retained earnings | -$44.9M | -$71.7M | -$144M | -$347M | -$338M | -$368M | -$449M | -$515M |
| Shares (wtd avg diluted) | 10.7M | 15.1M | 26.2M | 26.3M | 27.1M | 26.6M | 27.0M | 27.4M |
Every figure is extracted from Arcturus Therapeutics Holdings Inc.’s annual reports as filed with the SEC (XBRL company facts) — no third-party estimates. Fiscal years are labeled by period end; filers occasionally re-tag concepts, so a sparse cell means the company didn’t report that concept for that year. Free cash flow = operating cash flow − capital expenditures.
Research and education only — not financial advice. TENKis not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities TENK rates; see Disclosures. Past performance does not guarantee future results. Do your own research.